Pages that link to "Q28372143"
Jump to navigation
Jump to search
The following pages link to Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption (Q28372143):
Displaying 50 items.
- Biomarkers predicting antidepressant treatment response: how can we advance the field? (Q27026147) (← links)
- Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters (Q28363795) (← links)
- Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans (Q28544844) (← links)
- P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents (Q30544869) (← links)
- Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. (Q32181067) (← links)
- Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. (Q33726019) (← links)
- Blood-brain barrier active efflux transporters: ATP-binding cassette gene family (Q33985133) (← links)
- Drug resistance in brain diseases and the role of drug efflux transporters. (Q33988704) (← links)
- The ABCB1 transporter gene and antidepressant response (Q34062379) (← links)
- Pharmacogenetics of antidepressant response (Q34155796) (← links)
- What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? (Q34172972) (← links)
- Is there a role for 5-HT1A agonists in the treatment of depression? (Q34174041) (← links)
- Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation (Q34303346) (← links)
- Drug efflux transporters in the CNS. (Q34530624) (← links)
- The clinical pharmacokinetics of escitalopram (Q34610822) (← links)
- Pharmacogenetics of antidepressants (Q35026088) (← links)
- In vitro and in vivo models for assessing drug efflux transporter activity (Q35048743) (← links)
- Antidepressant drug discovery in the postgenomic era. (Q35066464) (← links)
- The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. (Q35236618) (← links)
- From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes (Q35680883) (← links)
- Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings (Q35708089) (← links)
- Therapeutic implications of the MDR-1 gene (Q35925779) (← links)
- Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report (Q35965584) (← links)
- Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. (Q36036389) (← links)
- Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients (Q36325439) (← links)
- Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling (Q36341660) (← links)
- Pharmacogenomics and antidepressant drugs (Q36438205) (← links)
- The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases (Q36510902) (← links)
- Antidepressant-drug interactions are potentially but rarely clinically significant (Q36538987) (← links)
- Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance (Q36582619) (← links)
- The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord (Q36590671) (← links)
- ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression (Q36591193) (← links)
- Pharmacogenetics of chronic pain and its treatment. (Q36900075) (← links)
- A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoprotein (Q36914175) (← links)
- Transporter-mediated uptake into cellular compartments (Q36985076) (← links)
- The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. (Q37024001) (← links)
- Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics (Q37298913) (← links)
- Mechanisms of antidepressant resistance (Q37334088) (← links)
- Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior (Q37514340) (← links)
- Pharmacogenetics of antidepressant drugs: current clinical practice and future directions (Q37989490) (← links)
- An update on the ability of St. John's wort to affect the metabolism of other drugs (Q38011191) (← links)
- Psychotropic drug-drug interactions involving P-glycoprotein (Q38047816) (← links)
- A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice (Q38290046) (← links)
- Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy (Q38440275) (← links)
- The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study (Q38453405) (← links)
- Treatment-resistant depression: are animal models of depression fit for purpose? (Q38569708) (← links)
- ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis (Q39021015) (← links)
- ABCB1 genotyping in the treatment of depression (Q39029387) (← links)
- Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability (Q39113007) (← links)
- ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram (Q39447754) (← links)